Surgical decisions should not be based solely on MRI findings because not all suspicious lesions on MRI are cancer, and suspicious lesions should be biopsied before a surgical plan is devised in order to avoid surgical overtreatment, according to guidelines published in the Journal of the National Comprehensive Cancer Network.
Surgical decisions should not be based solely on MRI findings because not all suspicious lesions on MRI are cancer, and suspicious lesions should be biopsied before a surgical plan is devised in order to avoid surgical overtreatment, according to guidelines published in the Journal of the National Comprehensive Cancer Network.
Among the recommendations is that MRI is not a substitute for screening or diagnostic mammography and, when indicated, diagnostic breast ultrasound, the guidelines state. But when cancer is found in the lymph nodes but not the breast, MRI can find the location of cancer in the breast in nearly 60% of women.
The guidelines were developed by Dr. Constance Lehman, a professor of radiology at the University of Washington and director of breast imaging at Seattle Cancer Care Alliance, and colleagues. They were based on an extensive review of published, peerreviewed studies.
Multicenter CT Study Shows Benefits of Emerging Diagnostic Model for Clear Cell Renal Cell Carcinoma
May 15th 2024Combining clinical and CT features, adjunctive use of a classification and regression tree (CART) diagnostic model demonstrated AUCs for detecting clear cell renal cell carcinoma (ccRCC) that were 15 to 22 percent higher than unassisted radiologist assessments.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.